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Bioequivalence of Topical Formulations in Humans:
Evaluation by Dermal Microdialysis Sampling and the
Dermatopharmacokinetic Method
Eva Benfeldt1, Steen H. Hansen2, Aage Vølund3, Torkil Menne´1 and Vinod P. Shah4,5,6
The aim of this study was to evaluate the relationship between dermal microdialysis (DMD) sampling and the
dermatopharmacokinetic method when employed simultaneously for bioequivalence (BE) investigations of
topical formulations. Topical lidocaine cream and ointment (both 5%) was investigated in eight healthy human
volunteers (four male, four female). On one forearm, four microdialysis probes in two penetration areas
sampled for 5 hours, and on the other arm, tape stripping was performed 30 and 120 minutes after product
application. Lidocaine content in samples was analyzed by HPLC–mass spectrometry. The two methods were in
agreement showing 3- to 5-fold higher lidocaine penetration from cream formulation than from ointment.
A rank-order correlation between the two methods was demonstrated for lidocaine contents in microdialysates
versus tape strip at 120 minutes, significant for the ointment formulation and for both formulations analyzed
together. Analysis of variance demonstrated reproducible lidocaine concentrations in microdialysates with an
intrasubject variability of 19% between probes and 20% between the two penetration areas. Thus, intersubject
variability accounted for 61% of the variance. DMD sampling proved effective and variability analyses
demonstrated the feasibility of BE studies in as little as 18 subjects.
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INTRODUCTION
The dermatopharmacokinetic (DPK) principle for bioequiva-
lence (BE) determination of topical drug products has come
under criticism that the measurement of drug represents the
concentration in ‘‘dead tissue’’. The primary aim of this
research was to evaluate the relationship between DPK and
dermal microdialysis (DMD) methodology, where the latter
represents the drug concentration in the living tissue.
We employ the DPK method (Shah, 2001), where tape-
stripping harvesting of stratum corneum (SC) samples the
outermost layers of the skin, with simultaneous sampling in
the dermis by microdialysis sampling. The sampling matrix is
thus essentially different, and the overall evaluation concerns
the relationship between the results obtained with the two
methodologies.
Second, we wished to evaluate the usefulness of DMD for
topical BE studies in human volunteers, and in particular to
identify and quantify the variability components.
Third, based on the results, we wished to estimate the
number of subjects or patients necessary in future micro-
dialysis protocols investigating BE of topical formulations in
healthy skin.
Background
In the determination of BE of topical products, the method of
choice is the tape-stripping technique, also called the DPK
method (Shah et al., 1998; Food and Drug Cosmetics Act,
2002). The method consists of a standardized protocol of
repeated applications and removal of adhesive tape on the
skin surface, whereby consecutive layers of SC cells are
sampled. Using analysis of each tape strip, it has been shown
that the drug concentration in the SC decreases loglinearly,
and that about 90% of the concentration is found in the first
10 strips. The next 10 strips contribute less than 5% (Caron
et al., 1990).
Auxiliary techniques can be used to further determine
the mass of SC cells or thickness removed by the
sampling procedure (Weigmann et al., 1999a, b), or by
quantification of SC mass by protein analysis of strips (Dreher
et al., 2005).
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In the application of the method for assessment of drug
penetration deeper than the cell layers of the SC, the
predictive value of the method relies on the studies by
Rougier et al. (1987). For compounds with different physico-
chemical characteristics, Rougier et al. have shown a good
correlation between the concentration in SC at 30 minutes
and their systemic absorption over 4 days (using radiolabelled
compounds and excretion collection and analysis).
This is particularly relevant for drugs aiming at an effect at
a deeper level in the epidermis or in the dermis as a target
organ. The DPK method has not been standardized for use in
diseased skin. The weakness of the DPK approach is the end-
point nature of the data obtained and the lack of studies
confirming the correlation between DPK data and clinical
efficacy.
Microdialysis technique has been introduced for studies of
dermal drug levels after topical drug administration in the last
decade (Ault et al., 1994; Groth, 1996; Cross et al., 1998;
Benfeldt, 1999). The method consists of placing an ultrathin,
semipermeable hollow fiber structure in the dermis and
perfusing this fiber, called a probe, with a tissue-compatible
sterile buffer at a very low rate by means of a microdialysis
pump (a very precise syringe driver). The probe will function
as an ‘‘artificial vessel’’ in the dermis and thus exchange
small, diffusible molecules from the probe to the tissue and
vice versa according to laws of simple diffusion (Ungerstedt,
1984; Benveniste and Huttemeier, 1990). The recovery of a
given compound closely reflects the concentration of un-
bound, that is, pharmacologically active, compound in the
intercellular fluid of the tissue surrounding the probe. For a
review of microdialysis in drug research, see Joukhadar and
Muller (2005). For the set-up in the current study, see
Figure 1.
The DMD method can provide very detailed chronologi-
cal pharmacokinetic data and several sampling sites can be
studied simultaneously in the same volunteer. The method is
currently undergoing rapid development in topical drug
penetration research (for a review of microdialysis methodo-
logy in skin research, see Groth et al., 2006).
The method can be challenging when used for sampling
very lipophilic or very highly protein-bound drugs due to low
recoveries of these compounds (Benfeldt and Groth, 1998),
and it requires training of laboratory personnel to obtain the
low variability demonstrated in some studies (Benfeldt,
1999). DMD is comparatively more invasive than DPK.
DMD can be performed in barrier perturbed or diseased skin.
Kreilgaard et al. (2001) published the first human study
demonstrating the potential of DMD for BE studies of topical
formulations in 2001.
Similar to DPK, for BE studies DMD also allows the testing
of both T (test) and R (reference) product at the same time in
the same individuals.
Figure 1. Linear microdialysis probes in situ in the dermis. The length
accessible to microdialysis sampling is 3 cm. A microdialysis pump provides
the perfusate flow of 1.25 ml/minute. Samples of 25ml are collected every
20 minutes for 5 hours. At t¼ 0, the topical formulation is applied in a dose of
4 mg/cm2 and left throughout the experiment. Markings for insertion of the
guide cannula are circles in order to avoid the introduction of a tattoo.
500
400
300
200
100
0
Li
do
ca
in
e 
co
nc
en
tra
tio
n 
(ng
/m
l)
–10 30 70 110 150 190 230 270
Time (minutes)
probe 4-cream
probe 3-cream
probe 2-cream
probe 1-cream
probe4-ointment
probe3-ointment
probe2-ointment
probe1-ointment
Figure 2. Raw microdialysate concentration data from the two separate experiments conducted in one volunteer. In blue–green, the lidocaine concentration
in dialysates from the four probes following topical application of the 5% cream formulation. In orange, the lidocaine concentration in the dialysates from
the four probes sampling topical penetration form the 5% ointment formulation. The sample concentration is plotted at mid-interval by convention.
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In order to evaluate the relationship between the
two methodologies, two formulations known to have
different drug penetration profiles (cream and ointment with
the same 5% concentration of the active compound) were
selected.
RESULTS
Pharmacokinetics obtained by DMD sampling
Both cream and ointment formulation provided measurable
dermal concentrations of lidocaine in the dialysates; the
result from one subject is shown in Figure 2. Following
topical drug application at t¼0, very rapid dermal drug
delivery is seen, providing lidocaine concentrations above
the limit of detection sampled only 20 minutes after applica-
tion of the formulation in most microdialysates.
The cream formulation provided rapid penetration with an
almost 5-fold higher area under the curve (AUC) than the
ointment formulation. For the whole group of subjects, the
pharmacokinetics are shown for both formulations in Figure 3
and summarized in Table 1.
Tmax has a higher value and smaller variance for ointment
than for cream formulation. Conversely, for the cream
formulation, the variance for lag time is large, as lag time is
generally shorter for cream formulation and values thus
lower.
No significant differences in AUC were present between
the four probes or the two areas.
Analysis of possible co-variables
Measurements of skin thickness and probe depth (Figure 4)
did not show any significant correlation with microdialysis
kinetics. A difference in skin thickness between the cream
group (1.3970.01 mm; mean7SEM) and the ointment group
(1.4870.01 mm) could be attributed to the hydrating effect of
the occlusive ointment formulation. The measurement was
performed at the end of the experiment.
Measurements of probe depth demonstrated highly accu-
rate placement horizontally within the dermis at a depth of
0.9170.02 mm in the cream series, 0.8370.01 mm
(mean7SEM) for the ointment series. This slight difference
in mean depths between the two groups, which we attribute
to a time effect of increased routine in probe insertion during
the series of experiments, had no significant effect on
lidocaine measurements.
Analyses of the influence of remaining co-variables (actual
dose applied, gender, age, room temperature, and humidity;
70 possible correlations) were without significant findings of
any effect on lidocaine kinetics, sampled by microdialysis.
The prilocaine concentration in the perfusate, added as a
calibrator for estimation of lidocaine recovery by the probe,
proved to be of no advantage owing to an inexpedient
procedure during the initiation of the experiment. Owing to
inadequate flushing out of the dead space in the inlet tubing
of the probe, the prilocaine concentration in the initial
microdialysis samples was very variable and reflected
variable calibrator concentration in the perfusate and not
loss of calibrator as intended. Hence, we chose not to use
prilocaine data to correct lidocaine recovery data.
The average recovery by loss of prilocaine between 110
and 290 minutes, once the dead space was cleared, was 70%.
The intraindividual coefficient of variation (CV) for prilocaine
Table 1. Pharmacokinetics by dermal microdialysis
AUC
(ng/ml min)
Cmax
(ng/ml)
Tmax
(min)
Lag time
(min)
Cream
Mean 15,983 112 243 26.0
CV (%) 41 41 5 18
95% CI 6,317–444,835 44–3,132 214–272 20.2–31.9
Ointment
Mean 3,309 27.5 275 45.6
CV (%) 42 41 2 27
95% CI 1,271–8,612 11–71 260–290 26.6–64.6
Paired t-test P-value 0.018 0.030 0.006 0.060
AUC, area under the curve; CV, coefficient of variation; CI, confidence
interval.
Number of subjects: 8.
AUC and Cmax were log transformed and geometric means are shown.
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Figure 3. Different penetration from the two formulations: DMD methodology. (a) Pharmacokinetics obtained by microdialysis, showing the dermal lidocaine
penetration from the cream (solid black) and ointment (red line) for all volunteers (n¼ 8). Means with SEM in log-scale. (b) Mean AUC with SEM for cream
(black) and ointment (red) formulation, sampled by microdialysis.
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recovery by loss was 13% and the interindividual CV was
16%.
Pharmacokinetics by the DPK method
The tape-stripping procedure provides two end-point mea-
surements for each formulation, but robustly discriminates
(Figure 5) between cream and ointment formulations. For
cream formulation, the penetration measured by the DPK
method at 30 minutes was 9678.4 mg (mean7SEM), which is
significantly different from ointment formulation: 3571.5 mg
(Po0.0001).
Similarly for 120 minutes, cream formulation 10279.1 mg
was significantly different from ointment 4172.9 mg
(P¼0.0004).
Correlation between the two methods used
Both methods provided the same overall result, with the 5%
cream formulation delivering 2.5- to 3-fold more lidocaine to
the skin when investigated by the DPK method (significant
difference; Pp0.0001) and a 4.8-fold difference when
investigated by microdialysis methodology at the same time
in the same volunteers (significant difference; P¼ 0.018 and
0.030 for AUC and Cmax, respectively).
Thus, correlations between the two methods were
expected to exist, and pharmacokinetic parameters from
DMD were tested against DPK results for both 30- and 120-
minute samples (Table 2). Significant correlations were
present only with ointment formulation tape strip 120 minutes
and AUC, Cmax, or their logarithms. For dermal microdialy-
sate levels versus tape-strip samples, both at 120 minutes, a
significant correlation could be seen for cream and ointment
data (Figure 6). The correlation is weaker for the cream
formulation, for which a higher variability was found by both
DMD and DPK methodologies.
When analyzing the correlations using either individual
MD sampling points or MD AUC(0–t) versus DPK results, these
correlations were significant for all time points for ointment,
whereas correlations were weaker for the two formulations
analyzed together, and absent for cream formulation alone
(for details, see Table S1).
BE evaluation by the two methods
Cream and ointment formulations are not qualitatively the
same, and therefore the two formulations should not be tested
for BE as such. However, ruling out that they are BE can
demonstrate the applicability of both DMD and DPK
methodologies in BE evaluation. For the two formulations
to be BE, the 90% confidence interval (CI) for the ratio
between the AUCs must be between the boundaries of 80
and 125% (Schuirmann, 1987).
For microdialysis methodology
The two formulations were tested on two separate occasions
in the same eight individuals.
For each person, the difference in log AUC between cream
and ointment was calculated. The mean difference in
log AUC was 1.57570.515 (mean7SEM, 90% CI
0.599–2.551), and the mean ratio for all subjects was 4.83.
The 90% CI for the ratio cream/ointment is the antilog of
the previous interval 1.82–12.82. Thus, the bioavailability of
lidocaine from the cream formulation, relative to the
ointment, is 483% with a 90% CI of 182–1,282%. The two
Figure 4. Ultrasound scanning image of two probes in the dermis in one
treatment area. The depth of the probes, measured from the entrance echo
of the epidermis, is 0.75 mm (upper) and 0.74 mm (lower). The thickness of
the skin (dermis and epidermis) is 1.5 mm.
Table 2. Correlations between microdialysis and tape-strip data
Cream formulation Ointment formulation
Tape strip 30 Tape strip 120 Tape strip 30 Tape strip 120
r P r P r P r P
AUC 0.12 40.50 0.23 40.50 0.45 0.27 0.80 0.016
log AUC 0.21 40.50 0.22 40.50 0.18 40.50 0.85 0.0072
Cmax 0.27 40.50 0.11 40.50 0.33 0.42 0.80 0.016
log Cmax 0.27 40.50 0.13 40.50 0.11 40.50 0.84 0.0087
Tmax 0.80 0.017 0.39 0.35 0.24 40.50 0.51 0.19
Lag time 0.07 40.50 0.27 40.50 0.13 4 0.50 0.64 0.086
TS30 — — 0.29 0.49 — — 0.38 0.35
AUC, area under the curve.
The values in bold are significant correlations, the remaining are not.
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formulations are therefore not BE, and cannot be regarded as
interchangeable.
For the DPK method
In a similar fashion, the DPK data obtained for the two
formulations can be compared with BE evaluation methodo-
logy in order to reject BE.
For DPK 30 minutes: Mean ratio for cream/ointment is
2.72, the CI for the difference is 0.849–1.150, and the interval
for the ratio is the antilog: 234–316%. This is outside of the
80–125% BE criteria.
For DPK 120 minutes: Mean ratio for cream/ointment is
2.48, the CI for the difference is 0.671–1.146, and the interval
for the ratio 196–315%.
Imagining that the two formulations had indeed been
similar, and the ratio had been 1, then the above intervals for
the ratio would have been 86–116 and 79–127%, which
would mean fulfillment of the BE criteria for DPK 30 minutes,
but just not fulfillment for DPK 120 minutes. As cream and
ointment are two different types of formulations, they should
not be tested for BE. The above calculation just illustrates that
the two formulations are not BE.
Analysis of variability components in microdialysis sampling
The design of the study facilitated identification of the various
components that are integrated in the overall variability of
microdialysis sampling of topical drug penetration. The
analysis by the variance component model demonstrates
the intrasubject variability of 19% between probes and 20%
between the two penetration areas. Thus, the intersubject
variability accounted for the remaining 61% of the variance
observed.
Calculations of sample size for topical BE studies by
microdialysis sampling
Based on the analysis of variance above, the number of
subjects necessary for a BE study of two formulations by
microdialysis can be calculated (Table 3). The huge
difference in number of subjects needed, depending on
whether the formulations are tested one at a time or
simultaneously in the same subject, reflects the impact of
the interindividual differences in topical drug penetration,
probably founded in differences in the skin barrier function.
The calculated number of 18 subjects for a BE study with
three probes in each test area is based on the variability
observed in the current study (ointment data set).
DISCUSSION
The result obtained by DPK, shown in Figure 5, demonstrates
that there is no significant difference in SC concentration of
lidocaine after 30 and 120 minutes. The result also shows that
there is a significant difference in SC content of lidocaine
between cream and ointment, around 2.5-fold.
The AUC measured by DMD represents the total amount
of drug that has penetrated through epidermis and diffused
into the dermis over the 5-hour period. The AUCs for 5%
lidocaine cream and ointment are significantly different, with
the AUC for the cream being almost 5-fold higher than for the
ointment (Figure 3).
Thus, an excellent rank-order correlation is found between
the DPK result and the DMD result in this paper, which is
state-of-the-art in BE of topical products.
These results provide an answer to the DPK critiques. In
May 2002, the FDA Draft Guidance Document on ‘‘Pharmaco-
kinetics Applied to Drug Concentration Measurements in
Stratum Corneum (SC)’’ was withdrawn. This was in part
owing to lack of correlation between the drug concentration
in SC (by DPK) and clinical efficacy and partly owing to the
finding of different DPK results from lab to lab. This latter
issue has recently been attributed to the lack of standardiza-
tion of procedures (Shah, 2005).
The DPK variability in the present study was low (CVs
between 12–25%, lowest for ointment). The variability for
DPK methodology can be around 50% (Pershing et al., 2003).
The DMD variability, expressed as CV for AUC, in studies
of topical drug penetration has previously been found to be
56–61% (Kreilgaard et al., 2001), and the variability has been
demonstrated to be introduced by individual drug penetration
properties (variability in the skin barrier) in a DMD study in
hairless rats (Simonsen et al., 2003).
For the parameters AUC and Cmax, we have found CVs
around 41% (Table 1), and the study design allowed for very
accurate analysis of each variability component.
A clear conclusion from the present study is that individual
differences in skin barrier function have a large impact (61%
of the overall CV) on the variability in topical drug
penetration. In order to further characterize the cause(s)
of this variability, auxiliary non-invasive measurements of
skin temperature, trans-epidermal water loss, colorimetry,
blood flow by laser-Doppler perfusion imaging, or even
evaluation of SC thickness by tape stripping (Kalia et al.,
2001) could be undertaken before or preferably during the
DMD experiments.
We investigated two formulations containing a small,
relatively hydrophilic compound of interest. When closely
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Tape strip 30 minutes Tape strip 120 minutes
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Figure 5. Different penetration from the two formulations: DPK
methodology. Pharmacokinetics by tape-stripping methodology. The mean
lidocaine content in cumulated tape strips is shown for cream (black) and
ointment (red) formulation (n¼8), sampled at t¼30 and 120 minutes. Error
bars are SEM.
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studied, we found significant correlations between the two
methods employed for the ointment formulation separately
and for the two formulations analyzed together, but no
significant correlations for the cream data set (apart from the
overall agreement in BE evaluation of the formulations).
In general, only high correlations (r40.8) can be shown
with as little as eight pairs of observations. With a larger
study, more correlations may be detectable. Drugs that form a
reservoir in the SC, or that only penetrate the epidermis to a
small degree, will not exhibit the correlation shown in this
study. Again, the two methods sample in different ‘‘compart-
ments’’ and are not likely to be interchangeable for any given
compound.
DMD is a step closer in providing drug concentrations
sampled at the site of action for topical drugs. In the FDA
criteria for evaluations of bioavailability (Food and Drug
Cosmetics Act, 2002), it is stated that for drugs not intended
to be absorbed into the bloodstream, measurements should
reflect the rate and extent to which the active molecule
becomes available at the site of action. The microdialysis
technique makes it possible to do exactly this, to sample in
the target organ, with real-time chronology.
This approach is far better than expensive clinical
trials currently required for generic drug approvals. To
gain adequate statistical power, they may require as many
as 300 patients (Shah et al., 1998). Employing the DPK
method, it has been estimated that between 40 and 50
subjects are needed for a BE study (Pershing et al., 2003).
Statistical calculations indicate that with DMD methodology,
BE studies with 90% CI and 80–125% BE limits can be
conducted in 27 subjects, using two probes in each test
area, or 18 subjects using three probes per formulation
application site.
The DMD and DPK method resulted in similar rank-order
correlation for the two products studied. This provided a
much-needed answer to DPK critiques for ‘‘measurements in
dead skin’’, as in the current study we establish that SC
concentration was predictive of the drug concentration in the
living part of the skin.
Future studies will be aiming at confirming this for other
formulations and other substances, and at exploring the
correlation between the two sampling methodologies further.
MATERIALS AND METHODS
Materials
Xylocaine cream and Xylocaine ointment (both 5% lidocaine)
formulations (AstraZeneca, Sweden) were used for topical application.
Sterile perfusate (phosphate-buffered isotonic saline, pH 6.5, with
added prilocaine 10 mg/l) was prepared by the Copenhagen County
Hospital Pharmacy in sealed 20 ml glass vials (D-Squame Standard
discs, 22 mm¼ 3.8 cm2 (Cuderm Corp., Dallas, TX)).
Study population
The study was performed in eight healthy human volunteers (four
male, mean age 34 years (range 29–37) and four female, mean age
49 years (range 46–55)). All subjects participated on two occasions,
where either cream or ointment was investigated, with a minimum
recovery period of 6 days. Subjects were free from skin disease, took
no regular medication, and refrained from using any topical
formulations the 3 days preceding an experiment.
Subjects were given a detailed description of the study and
written consent was obtained. The study was approved by the
Copenhagen County Ethical Committee (KA 02076gs) and the
Danish National Drug Review Board (j. no. 2612-2054), and it
was conducted according to the Declaration of Helsinki Principles
and in accordance with the Guidelines for Good Clinical Practice.
Microdialysis equipment
Linear microdialysis probes were manufactured in the laboratory
employing single fibers from hemodialysis cylinders (Hemophane,
Gambro GFS 16þ , Hechingen GmBH, Germany), outer diameter
216mm, molecular weight cutoff 2 kDa, inserted in Portex flexible
grade nylon tubing (Astra Tech, Denmark) and fixed with cyanoa-
crylate glue (Loctite). The probe was stabilized by an internal
stainless steel guide wire (0.10 mm diameter, Sandvik Steel, Norway)
and prepared 1–3 days before the experiment. (Regarding the effect
of an internal wire, see (Klimowicz et al., 2004.)
Table 3. BE study size estimates
BE study with two formulations in each subject
Probability (%)
Limits of
variation (%)1
Two probes
per area
Three probes
per area
80 o25 (80–125%) 20 14
80 o33 13 9
80 o50 8 6
90 o25 27 18
90 o33 17 12
90 o50 10 7
95 o25 33 23
95 o33 21 15
95 o50 12 8
BE study with one formulation in each subject
80 o25 (80–125) 711 695
80 o33 427 417
80 o50 216 211
90 o25 985 962
90 o33 591 577
90 o50 299 292
95 o25 1,244 1,215
95 o33 746 729
95 o50 378 369
BE, bioequivalence.
Number of subjects required for BE determination of topical formulations
in healthy human volunteers, based on intraindividual (upper) and
interindividual (lower) variabilities.
1The limit of variation for equivalency determination described as
‘‘o25%’’ means less than factor 1.25 above and below the mean, thus
between 125% and 100/1.25=80%. The fourth row, with 90% probability
and limitation of variability to between 80 and 125%, corresponds to the
current FDA criteria for BE determination.
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The perfusate flow was provided from disposable syringes (2 ml)
placed in the microdialysis pumps (CMA/100, CMA/Microdialysis
AB, Stockholm, Sweden) and connected to the probes by Perifix
connectors (B Braun Medical, Germany).
For both in vitro and in vivo experiments, probes were sterilized
by immersion in 70% ethanol/water for 20 minutes and subsequently
used before drying.
Dialysate samples were collected in glass vials, capped
immediately after sampling, and stored frozen at 351C.
In vitro microdialysis recovery and loss
Relative recovery in vitro was established experimentally to ensure
reproducible and concentration-independent sampling of both lido-
caine and prilocaine (prilocaine to be employed as calibrator during
the in vivo experiments) (Larsson, 1991; Kreilgaard et al., 2001).
In brief, these experiments were conducted at room temperature,
employing magnetic stirrers (350 r.p.m.) in the plastic beakers with
lidocaine content in the medium and prilocaine in the dialysate. The
probes were prepared with 30 mm accessible dialysis membrane
length and a fixed perfusate flow rate of 1.25 ml/minute was
employed, both as used later for in vivo experiments.
Values obtained by in vitro microdialysis
Lidocaine: Relative recovery 8176% (two probes per concentration,
range 1–5–10–20–50 mg/ml). Prilocaine: Relative recovery by loss
2175% (two probes per concentration, range 1–5–10–20mg/ml).
There was no sign of either time or concentration dependence
and no evidence of interaction between lidocaine recovery and
prilocaine loss.
Experimental procedure
Following a standardized wash of the underarms with a drop of mild
liquid soap and drying the underarms without rubbing, the subject
lies in the supine position with the left arm placed on an armrest.
Line drawings on a transparent sheet, demarcating the placement of
the penetration areas on the forearms on Day 1, were used for
placing the areas well outside of these areas on Day 2.
Left arm: The 2.0 2.6 cm areas for topical drug application were
drawn on the skin with a felt tip pen and the entrance and exit points
for guide cannula insertion marked by circles (see Figure 1).
Employing sterile technique, the guide cannulae (22 G Microlance,
Becton Dickinson) were placed transversally across the volar
forearm in parallel pairs, 0.6 cm apart, in the two areas. Care was
taken to obtain a superficial and horizontal placement in the dermis.
The probes were taken from the ethanol bath and introduced in the
opposite direction through the guide cannulae, which were
subsequently withdrawn. Intradermal probe length after insertion
was 3.0 cm. After testing probe function, the entry and exit puncture
sites were sealed with a drop of cyanoacrylate glue (Sicomet
Tixotropic, Kemitura, DK) in order to prevent contamination from
topical drug formulation (see later). Perfusion of the probes was
started at a low flow rate of 0.2 ml/minute during the 1-hour recovery
period (Groth and Serup, 1998).
Before application of the formulation, the perfusate flow was
increased to 1.25 ml/minute and microdialysis sampling was started.
Right arm: The three areas for topical drug application were
marked on the skin by drawing around large Finn Chamber discs
with a felt tip pen and marked A, B, and C going distally on the
forearm. Areas A and B were randomized to 30/120 minutes. The
C area for control (blank) tape stripping nearest the wrist was
sampled (procedure, see below).
Application of formulation (t¼ 0): At t¼ 0, the formulation was
applied simultaneously to all test areas. Using pre-weighed glass
spatulas with a pre-weighed amount of formulation 3 mg in excess of
the intended dose (Mettler Toledo PB303), a dose of 4 mg/cm2 was
applied (12 mg to areas for tape stripping and 20 mg to microdialysis
areas).
Right arm: A fenestrated eye shield (ref. 0002, Aaron Medical, St
Petersburg, FL) was placed over the area due to be sampled at
120 minutes in order to protect against contamination. At 30 and
120 minutes, the tape-strip areas on the right arm were sampled.
Tape-strip procedure: Skin surface was wiped twice with cotton
gauze to remove residual formulation. Tape discs were applied and
removed by pincers, using gentle pressure with the blunt end after
application to assure good skin contact, and alternating strip removal
directions (N, S, E, and W). The first two discs were discarded and
discs 3–12 stacked and placed in an airtight glass container and
stored at 351C.
Left arm: Continuous microdialysis sampling was started at a
perfusion flow rate of 1.25 ml/minute and samples collected every
20 minutes for 5 hours.
At the end of the experiment, the probes were disconnected from
the pumps, ultrasound scanning was performed, probes were
removed, and a small bandage applied to protect the insertion areas
the remainder of the day.
Room temperature and humidity were recorded at the start and
end of the experiment.
Ultrasound scanning
High-frequency B-mode ultrasound scanning images using the
Dermascan C (Cortex, Denmark) (Serup et al., 1995) were obtained
at the end of the experiment (Figure 4). As described previously
(Benfeldt et al., 1999), using the A-mode interface, measurements of
probe depth and skin thickness were performed in triplicate over
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Figure 6. Correlation between DMD and DPK methodologies. Correlation
between drug content in tape-strips, sampled at 120 minutes, versus dermal
drug levels, sampled by microdialysis, at 120 minutes. Solid black, cream
formulation (r¼ 0.33, P¼ 0.42), red circles, ointment formulation, (r¼0.82,
P¼ 0.013) and both combined (r¼ 0.75, P¼ 0.0007).
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each probe (over the first, middle, and last third of the probe length
in the skin). All values concerning probe depth and skin thickness
are thus mean of three measurements.
Analysis of samples
Chemicals: Acetonitrile, ammonium acetate, acetone, and formic
acid were obtained from Merck (Darmstadt, Germany) and were of
analytical reagent grade.
Liquid chromatography–mass spectrometry method: Apparatus:
Agilent 1100 HPLC system equipped with a diode array detector and
a single quadrupole mass spectrometer.
Column: Phenomenex Aqua C18, 3mm, 100 4.6 mm. Mobile
phase: acetonitrileþ 25 mM ammonium acetate (40:60 v/v). Flow
rate: 0.5 ml/minute. Column temperature: 401C. UV detection:
250 nm.
The mass spectrometer was operated in the positive electro spay
mode with single ion monitoring at 235.1 mass units. Further
settings: fragmentor: 70; Vcap: 1200; drying gas: 10 l/minute;
nebulizer: 40.
Sample preparation: Microdialysates were collected in the micro-
autosampler vials used in the HPLC autosampler and 10 ml dialysate
was injected onto the HPLC column.
Limit of detection: 0.1 ng/ml. Limit of quantification: 0.5 ng/ml.
Analysis of tape-strip samples: To the tape strips (10 pieces on top
of one another), 10.0 ml of acetone was added. After treatment in an
ultrasonic bath for 30 minutes, the mixture was left overnight and re-
treated in the ultrasonic bath for 30 minutes. Then, 15.0 ml of 0.1%
formic acid was added and after mixing the mixture was centrifuged
for 5 minutes at 16,000 g. A 10 ml portion of the supernatant was
injected onto the HPLC column.
Statistical analyses
For microdialysis pharmacokinetic data, the area under time versus
concentration curve (AUC) was calculated by the trapezoidal
method and the lag time was the time when the concentration
exceeded the lower limit of quantification (0.5 ng/ml). Tmax was the
time corresponding to the single highest microdialysate lidocaine
concentration observed.
Preliminary analysis showed that the SD increased proportionally
with the mean for all parameters except Tmax and lag time. These
parameters were thus log-transformed to achieve variance
homogeneity, which is required for the analysis of variance
and calculation of variance components within and between
subjects. For log-transformed data, CVs were calculated as
CVð%Þ ¼ 100
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
expðSD2Þ  1
q
, where SD2 is the variance of the
log-transformed observations. Geometric means of log-transformed
data were calculated as antilog of the means of the log-transformed,
and confidence limits were likewise calculated as antilog of the
confidence limits of the log-transformed data. Paired t-tests were
used for comparison of cream and ointment results, and correlations
were analyzed by regression methods. P-values 40.05 were
considered insignificant. Statgraphics version 4 (Maneugistics,
Rockville, MD) was used for the statistical analyses.
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